Oxford Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Oxford Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,308	Closed	-$128K	–	381
2026 Q1	$128K	Buy	+10,308	New	+$138K	0.05%	413
2025 Q2	–	Sell	-20,725	Closed	-$174K	–	525
2025 Q1	$174K	Sell	20,725 -34,801	-63%	-$290K	0.08%	376
2024 Q4	$440K	Buy	+55,526	New	+$466K	0.2%	180
2020 Q1	–	Sell	-270,657	Closed	-$1.3M	–	276
2019 Q4	$1.3M	Buy	270,657 +131,945	+95%	+$459K	0.04%	693
2019 Q3	$402K	Buy	+138,712	New	+$484K	0.01%	1346
2019 Q1	–	Sell	-28,792	Closed	-$390K	–	1641
2018 Q4	$390K	Buy	+28,792	New	+$519K	0.01%	1297
2018 Q3	–	Sell	-108,303	Closed	-$1.79M	–	1674
2018 Q2	$1.79M	Buy	+108,303	New	+$1.9M	0.03%	730

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Oxford Asset Management's AMRX Position: Q2 2026 in Review

Oxford Asset Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 10,308 shares — an estimated $128K sold.

Oxford Asset Management first reported a position in AMRX in Q2 2018 and held it in 7 quarters. The position peaked at $1.79M in Q2 2018. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Oxford Asset Management reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Oxford Asset Management sold 10,308 Amneal Pharmaceuticals shares in Q2 2026, an estimated $128K.
Oxford Asset Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Oxford Asset Management's Amneal Pharmaceuticals position peaked at $1.79M in Q2 2018.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.